A Study of LY2835219 in Participants With Cancer
Neoplasm, Neoplasm Metastasis
About this trial
This is an interventional basic science trial for Neoplasm focused on measuring advanced cancer, metastatic cancer
Eligibility Criteria
Inclusion Criteria:
- Have histological or cytological evidence of cancer (solid tumors) that is advanced and/or metastatic
- Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
Exclusion Criteria:
- No symptomatic central nervous system (CNS) malignancy or metastasis
Sites / Locations
- Accelerated Comm. Oncology Research Network (ACORN)
- The West Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Abemaciclib Alone Period 1
Abemaciclib + Clarithromycin Period 2
Abemaciclib Safety Extension
50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.